The NLRP3 inflammasome is a critical component of innate immunity that senses diverse pathogen- and host-derived molecules. However, its aberrant activation has been associated with the pathogenesis of multiple diseases, including cancer. In this study, we designed and synthesized a series of aryl sulfonamide derivatives (ASDs) to inhibit the NLRP3 inflammasome. Among these, compounds , , and specifically inhibited NLRP3 activation at nanomolar concentrations without affecting the activation of the NLRC4 and AIM2 inflammasomes. Furthermore, we demonstrated that these compounds reduce interleukin-1β (IL-1β) production and attenuate melanoma tumor growth. Moreover, metabolic stability in liver microsomes of , , and was studied along with plasma exposure in mice of the most interesting compound . Therefore, we generated potent NLRP3 inflammasome inhibitors, which can be considered in future medicinal chemistry and pharmacological studies aimed at developing a new therapeutic approach for NLRP3 inflammasome-driven cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.3c00175DOI Listing

Publication Analysis

Top Keywords

nlrp3 inflammasome
16
aryl sulfonamide
8
sulfonamide derivatives
8
inflammasome inhibitors
8
nlrp3
6
novel aryl
4
derivatives nlrp3
4
inflammasome
4
inhibitors potential
4
potential treatment
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!